China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SHE:000999)
China flag China · Delayed Price · Currency is CNY
25.17
-0.10 (-0.40%)
Aug 11, 2026, 2:25 PM CST

SHE:000999 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
3,4213,3682,8532,4492,055
Depreciation & Amortization
1,173723.19786.67522.66478.75
Other Amortization
257.19177.0767.1148.7545.84
Loss (Gain) From Sale of Assets
-6.5-31.43-0.81-2.28-0.85
Asset Writedown & Restructuring Costs
52.9319.7288.9799.8152.33
Loss (Gain) From Sale of Investments
-227.41-26.0528.63-2.58-5.04
Provision & Write-off of Bad Debts
36.5382.8755.045.5313.63
Other Operating Activities
878.45595.17467.94102.6200.43
Change in Accounts Receivable
748.84-1,243633.69-71.84-674.74
Change in Inventory
385.9667.83-966.01-59.69-652.26
Change in Accounts Payable
-1,154682.7315.29-21.86458.43
Operating Cash Flow
5,5134,4024,1923,0061,885
Operating Cash Flow Growth
25.24%5.02%39.43%59.52%-15.26%

Investing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-1,271-790.07-857.21-951.57-872.6
Sale of Property, Plant & Equipment
8.035.1726.431.784.56
Cash Acquisitions
-5,251-953.63-11.76-120.63
Divestitures
-5.24-4.25--
Investment in Securities
-1,093-424.16-953.36-1,584-870.37
Other Investing Activities
202.1678.6532.7766.466.74
Investing Cash Flow
-7,410-1,130-793.5-2,479-1,792

Financing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Long-Term Debt Issued
6,5441,0073,578593.6997.97
Total Debt Issued
6,5441,0073,578593.6997.97
Short-Term Debt Repaid
-500-4.2-17.05-1.45-3.1
Long-Term Debt Repaid
-3,254-2,771-1,930-520.27-105.43
Total Debt Repaid
-3,754-2,775-1,947-521.72-108.53
Net Debt Issued (Repaid)
2,790-1,7681,63171.98-10.56
Issuance of Common Stock
-10-150.610.18
Repurchase of Common Stock
-35.15-2.21---
Common Dividends Paid
-1,256-2,834-1,056-855.78-505.66
Other Financing Activities
64.52-33.92-124.9857.75-162.98
Financing Cash Flow
1,564-4,629450.42-575.45-669.02

Net Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-11.872.885.016.35-2.31
Net Cash Flow
-344.99-1,3543,854-41.93-578.98

Free Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
4,2423,6123,3352,0551,012
Free Cash Flow Growth
17.43%8.33%62.28%103.03%-36.83%
Free Cash Flow Margin
13.42%13.08%13.48%11.37%6.51%
Free Cash Flow Per Share
2.552.172.001.230.61
Levered Free Cash Flow
-387.512,494149.871,53473.83
Unlevered Free Cash Flow
-313.992,544200.361,54782.7

Additional Metrics

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
3,2932,7012,7621,8391,919
Change in Working Capital
-72.39-506.25-154.74-216.92-955.53